Drugs / JNJ 49095397
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01661244 | Sep 2012 → Feb 2013 | chronic obstructive pulmonary disease | Respivert Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01230645 | Oct → Dec 2010 | respiratory syncytial virus infectious disease | Respivert Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01867762 | Sep 2013 → Aug 2014 | chronic obstructive pulmonary disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01475292 | Nov 2011 → Apr 2012 | chronic obstructive pulmonary disease | Respivert Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01230619 | Oct → Nov 2010 | seasonal allergic rhinitis | Respivert Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ 49095397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867762 ↗ |
| Known as | RV568 | “An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease” NCT01867762 ↗ |
| Modality | Small molecule | — CHEMBL3695568 ↗ |
| Route | Intranasal | “administered as nasal drops” NCT01230619 ↗ |